Addex shares are trading lower after the company announced the Phase 2 ADX71149 epilepsy study did not achieve statistical significance for the primary endpoint of time for patients to reach baseline seizure count when ADX71149 was added to standa...
ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS +3.59% Pre
ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS ADXN | 10.67 10.67 | +3.59% 0.00% Pre |
Addex shares are trading lower after the company announced the Phase 2 ADX71149 epilepsy study did not achieve statistical significance for the primary endpoint of time for patients to reach baseline seizure count when ADX71149 was added to standard of care.
